Proteomics International Laboratories Limited

Equities

PIQ

AU000000PIQ0

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
1.15 AUD +6.48% Intraday chart for Proteomics International Laboratories Limited +5.99% +28.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Proteomics International Signs Agreement with University of Oxford for Endometriosis Study MT
Proteomics Says PromarkerD's US Launch Delayed MT
Proteomics International Laboratories Secures ISO 13485 Certification Renewal MT
Proteomics International Laboratories Narrows Fiscal H1 Loss MT
Proteomics International Laboratories Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Proteomics International's Blood Test for Uterine Disease Undergoes Biomarker Validation MT
Proteomics International's Blood Test for Throat Cancer Undergoes Biomarker Validation MT
Proteomics International Laboratories Raises AU$6.5 Million for Test Commercialization, Further Development; Shares Down 10% MT
Proteomics Signs Deal to Sell PromarkerD in Chile; Shares Jump 5% MT
Proteomics International Laboratories Receives More than AU$1.8 Million R&D Tax Rebate MT
Proteomics International Laboratories Requests Extension of Securities Trading Suspension MT
Proteomics International Subsidiary Secures New Patent in Japan; Shares Fall 4% MT
Proteomics International Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Proteomics International Laboratories Signs Deal to Commercialize Diagnostic Test in the US; Shares Rally 11% MT
Proteomics International Laboratories Renews ISO 13485 Certification, ISO 17025 Accreditation MT
Proteomics International Laboratories Verifies Effectivity of Endometriosis Diagnostic Test MT
Proteomics International Laboratories to Resubmit Medicare Application for Diagnostic Test in Australia MT
Proteomics International Laboratories Limited Announces to Resubmit Application for PromarkerD Listing on Australian Medicare Benefits Schedule CI
Proteomics International Laboratories Limited Provides Update on Exclusive Licence Agreement with Sonic Healthcare USA, Inc CI
Proteomics International Laboratories Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Proteomics International Laboratories Extends Predictive Test Distribution Agreement in Britain MT
Proteomics International Laboratories Ltd Extends its Distribution Agreement with Apacor Limited to Bring its PromarkerD Predictive Test for Diabetic Kidney Disease to Patients in England, Scotland and Wales CI
Proteomics International Laboratories Limited Announces Letter of Intent with Sonic Healthcare USA Extended CI
Proteomics International Laboratories Raises AU$1.8 Million from Options Exercise MT
Proteomics International Laboratories Applies for Quotation of 50,000 Shares MT
Chart Proteomics International Laboratories Limited
More charts
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bio-analytical services. The Company specializes in proteomics, the study of the structure and function of proteins. The Company focuses on developing and commercializing diagnostic tests for chronic diseases. The Company operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. The PromarkerD test system is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Its Analytical Services includes a proteomics-based technology platform, used to test, and validate the protein composition of varied range of products.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.15 AUD
Average target price
1.38 AUD
Spread / Average Target
+20.00%
Consensus

Annual profits - Rate of surprise